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Available online 16 July 2015Reproducibility has always been a serious challenge when
medical researchers in both academia and industry have tried
to build upon previously published discoveries. Blindly chasing
faulty results has incurred a huge waste of human and mone-
tary resources. The damage to the progress of scientific dis-
coveries, as well as their application to human well-being,
cannot be overestimated. According to two reports by Bayer
and Amgen published in 2011 and 2012, 64e89% of the so-
called “landmark” results could not be reproduced in their
pre-clinical validation experiments.1,2 One plausible expla-
nation for this out of proportion irreproducibility is related to
the intricacy of the scientific experiments, including the
sourcing of reagent antibodies and cell lines, which are major
sources of variations. To make validation meaningful, the
study materials used in the original studies need to be
authenticated so that variations due to the faulty materials
can be prevented during follow-up studies. However, the
technical complexity and the costs of authentication often
discourage this practice in research laboratories. In addition to
these obstacles, researchers are left with no standards to
follow when validating their reagents and cell lines. Never-
theless, the ever-growing irreproducibility has created a sense
of urgency in themedical research field, and the root of faulty
science has to be tackled. Two recent commentaries inNature
and Nature Methods highlighted the importance of the quality
control of antibody reagents and cell lines.3,4 Both commen-
taries extensively discussed the existing quality problems
associated with antibody reagents and cultured cell lines. The
authors followed their discussions by advocating policy solu-
tions, as well as feasible standards, towards better authenti-
cation and validation. The main impetus of these discussions
will certainly raise the awareness of these problems, and may
change the attitudes among researchers, toward the goal of
improving the sourcing of antibodies and cell lines.
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